论文部分内容阅读
目的探讨氯沙坦对不稳定型心绞痛(UA)患者超敏C-反应蛋白(hs-CRP)、可溶性CD105(sCD105)的影响及意义。方法将68例UA患者随机分为对照组(n=30)及治疗组(n=38),对照组给予硝酸酯类、β受体阻滞剂、钙离子拮抗剂、阿司匹林、他汀类药物等常规治疗,治疗组在常规治疗基础上加用氯沙坦(100mg,1次/d),均治疗3个月。观察治疗前后hs-CRP、sCD105、胆固醇等变化及心绞痛发作情况。结果 2组患者心绞痛症状均明显改善,治疗组总有效率高于对照组(86.8%vs63.3%,P<0.05)。2组治疗后hs-CRP、sCD105水平均较治疗前明显下降(P<0.05,P<0.01),且治疗后治疗组hs-CRP、sCD105水平明显低于对照组(P均<0.05)。结论氯沙坦在常规治疗基础上治疗UA效果显著,可明显降低hs-CRP、sCD105,其机制可能与抗炎、稳定血管内皮及斑块等有关。
Objective To investigate the effect of losartan on the expression of hs-CRP and soluble CD105 (sCD105) in patients with unstable angina pectoris (UA). Methods Sixty-eight UA patients were randomly divided into control group (n = 30) and treatment group (n = 38). The control group was given nitrates, beta blockers, calcium antagonists, aspirin, statins and so on The patients in the treatment group were treated with losartan (100 mg once daily) on the basis of routine treatment for 3 months. The changes of hs-CRP, sCD105, cholesterol and angina pectoris before and after treatment were observed. Results The symptoms of angina were significantly improved in both groups. The total effective rate in the treatment group was significantly higher than that in the control group (86.8% vs63.3%, P <0.05). The levels of hs-CRP and sCD105 in the two groups were significantly lower than those before treatment (P <0.05, P <0.01), and the levels of hs-CRP and sCD105 in the treatment group were significantly lower than those in the control group after treatment (all P <0.05). Conclusion Losartan has a significant effect on the treatment of UA on the basis of routine treatment, and can significantly reduce hs-CRP and sCD105. The mechanism may be related to anti-inflammation, stable vascular endothelium and plaque.